Dasatinib for the Treatment of Moderate and Severe COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This phase II trial investigates how well dasatinib works in treating patients with moderate and severe COVID-19. Dasatinib is a drug used to treat chronic leukemia which may help reduce the strong inflammation caused by COVID-19 that can damage the lungs or other organs.
Epistemonikos ID: 1d56eb5d240a53fbbc6c712bb9c79915f935f007
First added on: Apr 06, 2021